<DOC>
	<DOCNO>NCT02623322</DOCNO>
	<brief_summary>This Phase 2 , randomize , double-blind , placebo-controlled single dose study otherwise healthy adult acute uncomplicated seasonal influenza A ass safety , efficacy , pharmacokinetics MHAA4549A .</brief_summary>
	<brief_title>A Study MHAA4549A Monotherapy Acute Uncomplicated Seasonal Influenza A Otherwise Healthy Adults</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<criteria>Otherwise healthy adult Positive test influenza A infection No 72 hour elapse onset influenzalike illness start study drug Presence least one moderate severe constitutional symptom headache , myalgia , fever , chill , fatigue , anorexia , nausea PLUS one moderate severe respiratory symptom cough , sore throat , rhinorrhea For woman childbearing potential : negative pregnancy test agreement use acceptable contraceptive method least 120 day study drug administration For men : agreement use acceptable contraceptive method least 30 day study drug administration Creatinine clearance less equal ( &lt; /= ) 80 milliliter per minute ( mL/min ) Any significant medical condition laboratory abnormality Clinical sign symptoms consistent otitis , bronchitis , sinusitis , pneumonia active bacterial infection Use antiviral therapy period onset influenzalike illness prior enrollment Pregnancy within 6 month prior Screening , breastfeed within 3 month prior Screening , currently pregnant Investigational therapy within 30 day 5 halflives prior start study drug , whichever great Prior antiinfluenza monoclonal antibody use Receipt nasal influenza A vaccine within 14 day prior Screening Positive test influenza B influenza A+B within 2 week prior study drug History significant tobacco use drug/alcohol abuse Chronic use oral inhaled corticosteroid within 30 day prior Screening Autoimmune disease , know immunodeficiency cause , use immunosuppressive medication History chronic respiratory condition Human immunodeficiency virus ( HIV ) cluster differentiation ( CD ) 4 count &lt; /= 200 cell per milliliter ( cells/mL ) past 12 month Serious infection require oral intravenous ( IV ) antibiotic within 14 day prior Screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>